Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow BIODESIX INC

Get SEC filing alerts via email and in your feed for BIODESIX INC

BDSX

BIODESIX INC

About BIODESIX INC

Biodesix, Inc. develops and commercializes blood-based diagnostic tests focused on lung disease, including lung cancer diagnosis, treatment guidance, and monitoring. Its core products combine proteomics, genomics, and AI technologies to provide personalized, timely clinical insights for healthcare providers and biopharmaceutical partners. Biodesix operates CLIA-certified labs in the U.S., serving pulmonologists, hospitals, and research institutions with proprietary tests that improve patient outcomes and reduce unnecessary procedures.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from BIODESIX INC

1
1
BIODESIX INC Biodesix Reports 42% Revenue Growth to $25.6 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
BIODESIX INC Biodesix Reports $88.5 Million Revenue for Fiscal Year 2025, 24% Increase from 2024

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
BIODESIX INC Biodesix Reports 20% Revenue Growth to $21.8 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
BIODESIX INC Biodesix Reports 12% Revenue Growth to $20M in Q2 2025, Despite Net Loss

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
BIODESIX INC Biodesix Reports $17.96 Million Revenue in Q1 2025, 21% Increase Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
BIODESIX INC Biodesix Reports 45% Revenue Growth to $71.3 Million for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
BIODESIX INC Biodesix Reports 35% Revenue Growth, Net Loss Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments